# Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Source: https://onco.cc/key-papers/paper-nct03907852-nat-med-2023/  
OnCo record `paper-nct03907852-nat-med-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the Phase 1 trial registered as NCT03907852, in Nature Medicine (2023), chosen as the most cited paper whose own text cites the registry id.

## Summary

The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors. The primary objectives were to evaluate safety and determine the recommended phase 2 dose (RP2D). Secondary objectives included efficacy. Thirty-two patients received gavo-cel at increasing doses either as a single agent (n = 3) or after lymphodepletion (LD, n = 29). Dose-limiting toxicities of grade 3 pneumonitis and grade 5 bronchioalveolar hemorrhage were noted. The RP2D was determined as 1 × 10 8 cells per m 2 after LD. Grade 3 or higher pneumonitis was seen in 16% of all patients and in none at the RP2D; grade 3 or higher cytokine release syndrome occurred in 25% of all patients and in 15% at the RP2D. In 30 evaluable patients, the overall response rate and disease control rate were 20% (13% confirmed) and 77%, respectively, and the 6-month overall survival rate was 70%. Gavo-cel warrants further study in patients with mesothelin-expressing cancers given its encouraging anti-tumor activity, but it may have a narrow therapeutic window. ClinicalTrials.gov identifier: NCT03907852.

Indexed on Europe PMC as PubMed record 37501016 (DOI 10.1038/s41591-023-02452-y). Its abstract cites the registry id NCT03907852, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature Medicine
- Year: 2023
- DOI: 10.1038/s41591-023-02452-y
- Authors: Hassan R, Butler M, O'Cearbhaill RE, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT03907852 with the most citations, so it is the natural first reading for anyone following the Phase 1 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Nat Med 2023: https://doi.org/10.1038/s41591-023-02452-y
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37501016/
- Europe PMC: https://europepmc.org/article/MED/37501016
- ClinicalTrials.gov NCT03907852: https://clinicaltrials.gov/study/NCT03907852

## Connected records

- trials: [Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer](https://onco.cc/trials/nct03907852/)
- journals: [Nature Medicine](https://onco.cc/journals/nature-medicine/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct03907852-nat-med-2023.json